Mandate

Vinge represented affiliates of American Industrial Partners in entering into an agreement to acquire Veoneer’s Restraint Control Systems business from SSW Partners

Veoneer is the world leader in automotive electronic restraint control systems and has sold more than 1 billion electronic control units and crash sensors. Veoneer’s scalable, best-in-class restraint control systems are saving lives by mitigating the effects of car crashes. In 2023, the company’s products are part of more than 40 scheduled vehicle launches. The company has approximately 2,700 employees in 11 countries.

AIP is a middle market private equity firm focused on industrial businesses. The firm manages over $16 billion on behalf of its limited partners and invests in the aerospace and defense, automotive, building products, capital goods, chemicals, industrial services, industrial technology, logistics, metals and mining, transportation and other sectors.

Vinges team consisted of Ulrich Ziche (M&A), Daniel Wendelson, Hilda Ivarsson, Alva Chambert (EU, Competition and Regulatory), Simon Söderholm (Employment & Benefits) and Marcus Eklund (Investigations & International Disputes).

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025